TRIL and diffuse large B-cell lymphoma: The results from our studied patient cohort, which is comparable in terms of basic patient and disease characteristics to transplant eligible r/rDLBCL patients treated within prior prospective trials [5,31,41] underline the hypothesis that conBMI expresses an easy to access surrogate for an underlying unfavorable lymphoma biology in the second-line setting of DLBCL and TRIL.